Citation: W. Clark et Mj. Kendall, THERAPEUTIC ADVANCES - RILUZOLE FOR THE TREATMENT OF MOTOR-NEURON DISEASE, Journal of clinical pharmacy and therapeutics, 21(6), 1996, pp. 373-376
Authors:
RAJMAN I
KENDALL MJ
CRAMB R
HOLDER RL
SALIH M
GAMMAGE MD
Citation: I. Rajman et al., INVESTIGATION OF LOW-DENSITY-LIPOPROTEIN SUBFRACTIONS AS A CORONARY RISK FACTOR IN NORMOTRIGLYCERIDAEMIC MEN, Atherosclerosis, 125(2), 1996, pp. 231-242
Citation: I. Rajman et al., ATHEROGENIC LOW-DENSITY-LIPOPROTEIN (LDL) SUBFRACTION PROFILES IN DIALYSIS PATIENTS, Journal of the American Society of Nephrology, 6(3), 1995, pp. 558-558
Citation: A. Head et al., EXERCISE METABOLISM DURING 1 HOUR OF TREADMILL WALKING WHILE TAKING HIGH AND LOW-DOSES OF PROPRANOLOL, METOPROLOL, OR PLACEBO, Clinical cardiology, 18(6), 1995, pp. 335-340
Authors:
HAFFNER CA
KENDALL MJ
STRUTHERS AD
BRIDGES A
STOTT DJ
Citation: Ca. Haffner et al., EFFECTS OF CAPTOPRIL AND ENALAPRIL ON RENAL-FUNCTION IN ELDERLY PATIENTS WITH CHRONIC HEART-FAILURE, Postgraduate medical journal, 71(835), 1995, pp. 287-292
Authors:
GREENHOW S
JAKEMAN PM
KENDALL MJ
DOWLING BA
FRANKLIN M
Citation: S. Greenhow et al., AN EVALUATION OF THE VARIABILITY IN PROLACTIN SECRETION IN RESPONSE TO THE SEROTONINERGIC AGONIST D-FENFLURAMINE IN MAN, Journal of physiology, 489P, 1995, pp. 44-44
Citation: Mj. Kendall, APPROACHES TO MEETING THE CRITERIA FOR FIXED-DOSE ANTIHYPERTENSIVE COMBINATIONS - FOCUS ON METOPROLOL, Drugs, 50(3), 1995, pp. 454-464
Authors:
JAKEMAN PM
HAWTHORNE JE
MAXWELL SRJ
KENDALL MJ
HOLDER G
Citation: Pm. Jakeman et al., EVIDENCE FOR DOWN-REGULATION OF HYPOTHALAMIC 5-HYDROXYTRYPTAMINE RECEPTOR FUNCTION IN ENDURANCE-TRAINED ATHLETES, Experimental physiology, 79(3), 1994, pp. 461-464
Citation: A. Head et al., EXERCISE METABOLISM IN HEALTHY-VOLUNTEERS TAKING ATENOLOL, HIGH AND LOW-DOSES OF METOPROLOL CR Z0K, AND PLACEBO/, British journal of clinical pharmacology, 38(6), 1994, pp. 499-504
Authors:
KENDALL MJ
SPANNUTH F
WALT RP
GIBSON GJ
HALE KA
BRAITHWAITE R
LANGMAN MJS
Citation: Mj. Kendall et al., LACK OF EFFECT OF H-2-RECEPTOR ANTAGONISTS ON THE PHARMACOKINETICS OFALCOHOL CONSUMED AFTER FOOD AT LUNCHTIME, British journal of clinical pharmacology, 37(4), 1994, pp. 371-374
Citation: Mj. Kendall et I. Rajman, A RISK-BENEFIT ASSESSMENT OF CELIPROLOL IN THE TREATMENT OF CARDIOVASCULAR-DISEASE, Drug safety, 10(3), 1994, pp. 220-232
Citation: Mj. Kendall et al., CARDIOPROTECTIVE THERAPEUTICS - DRUGS USED IN HYPERTENSION, HYPERLIPEMIA, THROMBOEMBOLISM, ARRHYTHMIAS, THE POSTMENOPAUSAL STATE AND AS ANTIOXIDANTS, Postgraduate medical journal, 70(823), 1994, pp. 329-343
Authors:
AKHLAGHI S
MAXWELL SRJ
KENDALL MJ
HUGHES B
GREENHAFF P
Citation: S. Akhlaghi et al., A COMPARISON OF THE BETA(1)-SELECTIVITY OF CONVENTIONAL METOPROLOL AND METOPROLOL CR DURING EXERCISE IN HEALTHY-VOLUNTEERS, Journal of clinical pharmacy and therapeutics, 18(4), 1993, pp. 259-266
Citation: I. Rajman et Mj. Kendall, SUDDEN CARDIAC DEATH AND THE POTENTIAL ROLE OF BETA-ADRENOCEPTOR-BLOCKING DRUGS, Postgraduate medical journal, 69(818), 1993, pp. 903-911
Authors:
WALT RP
KENDALL MJ
BRAITHWAITE R
LANGMAN M
Citation: Rp. Walt et al., LACK OF EFFECT OF H-2-RECEPTOR ANTAGONISTS ON THE PHARMACOKINETICS OFALCOHOL CONSUMED, Gastroenterology, 104(4), 1993, pp. 222-222